# A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parental (LAP) in Healthy Adult Subjects

> **NCT01754116** · PHASE1 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 43 (actual)

## Conditions studied

- Infection, Human Immunodeficiency Virus

## Interventions

- **DRUG:** GSK1265744 30 mg oral
- **DRUG:** Midazolam 3 mg oral + GSK1265744 30mg oral
- **DRUG:** GSK1265744 400 mg (200 nm)
- **DRUG:** GSK1265744 400 mg (1 micro m)
- **DRUG:** GSK1265744 400 mg (5 micro m)

## Key facts

- **NCT ID:** NCT01754116
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2014-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01754116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01754116, "A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parental (LAP) in Healthy Adult Subjects". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01754116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*